Operated Stem Cells and Their Use

JP2025524373A5Pending Publication Date: 2026-06-16UMOJA BIOPHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
UMOJA BIOPHARMA INC
Filing Date
2023-06-10
Publication Date
2026-06-16

AI Technical Summary

Technical Problem

Existing methods for producing cytotoxic innate lymphoid cells (CIL) are inefficient and require exogenous factors for differentiation and expansion, limiting their scalability and applicability in immunotherapy.

Method used

Genetically engineered stem cells expressing synthetic cytokine receptors for non-physiological ligands, such as rapamycin or rapalogs, which induce differentiation into hematopoietic precursors and CIL cells without the need for exogenous factors like SCF, TPO, BMP4, FGF, and IL-2, IL-7, IL-15, and IL-21, and provide resistance to rapamycin-mediated mTOR inhibition.

Benefits of technology

Enables large-scale production of CIL cells with desired functional characteristics for immunotherapy, enhancing differentiation and proliferation efficiency without external factors, and providing resistance to rapamycin.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0001_ABST
    Figure 00000000_0001_ABST
  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Compositions and methods are provided for a cell population comprising engineered stem cells comprising synthetic cytokine receptors for non-physiological ligands. The non-physiological ligands activate the synthetic cytokine receptors within the engineered stem cells to induce differentiation of the stem cells and expansion and / or activation of the resulting cytotoxic natural lymphocyte-like cells. TIFF2025524373000046.tif51159
Need to check novelty before this filing date? Find Prior Art